A subgroup of COVID-19 patients develop very severe disease with requirement for ICU treatment, ventilation, and ECMO therapy. Laboratory tests indicate that the immune and clotting system show marked alterations with hyper-activation, hyper-inflammation, cytokine storm development. Furthermore, organ-specific biomarkers demonstrate the involvement of cardiac muscle, kidney, and liver dysfunction in many patients. In this article the use of laboratory biomarkers is discussed with regard to their use for diagnosis, disease progression, and risk assessment.
- Skevaki, C.
- Fragkou, P. C.
- Cheng, C.
- Xie, M.
- Renz, H.
Keywords
- Betacoronavirus
- Biomarkers/analysis
- Coronavirus Infections/complications/*diagnosis/physiopathology
- Cytokines/analysis
- Disease Progression
- Humans
- Inflammation/complications/*virology
- Lung/virology
- Pandemics
- Pneumonia, Viral/complications/*diagnosis/physiopathology
- Risk Assessment
- *Biomarker
- *covid-19
- *Cytokine storm
- *Laboratory diagnosis
- *SARS-CoV2
- research funding from Hycor Biomedical and Thermo Fisher Scientific, research
- funding from Mead Johnson Nutrition (MJN), and consultancy fees from Bencard
- Allergie.
